Childhood Kidney Diseases

Korean Society of Pediatric Nephrology (대한소아신장학회)
권호 표지
DOI QR코드

DOI QR Code

Mechanism, clinical consequences, and management of dyslipidemia in children with nephrotic syndrome

  • Baek, Hee Sun (Department of Pediatrics, Yeungnam University College of Medicine)
  • Received : 2022.03.15
  • Accepted : 2022.04.24
  • Published : 2022.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Dyslipidemia in nephrotic syndrome (NS) is often characterized by marked increases in the levels of total cholesterol, triglycerides, low-density lipoprotein cholesterol, and other lipoproteins, such as very low-density lipoprotein, intermediate-density lipoprotein, and lipoprotein(a). It has been suggested that impaired catabolism of lipoproteins and cholesterol is mainly due to decreased lipoprotein lipase and hepatic lipase activity, and increased biosynthesis of lipoproteins in the liver. The management strategies for dyslipidemia in patients with NS consist of lifestyle modification, lipid-lowering agents represented by statins, second-line agents such as fibrates and bile acid sequestrants, and lipid apheresis. Compared with dyslipidemia in adult NS patients, whose risks of atherosclerotic disease and progressive renal injury are considered high, clinical data on dyslipidemia in pediatric NS patients are limited. Therefore, it is necessary to pay more attention to the evaluation and management of dyslipidemia in pediatric patients with NS in clinical practice.

Keywords

References

  1. Larkins NG, Liu ID, Willis NS, Craig JC, Hodson EM. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst Rev 2020;4:CD002290.
  2. Kang HG, Cheong HI. Nephrotic syndrome: what's new, what's hot? Korean J Pediatr 2015;58:275-82. https://doi.org/10.3345/kjp.2015.58.8.275
  3. Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol 2018;14:57-70.
  4. Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int 2016;90:41-52. https://doi.org/10.1016/j.kint.2016.02.026
  5. Vaziri ND, Yuan J, Ni Z, Nicholas SB, Norris KC. Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression. Clin Exp Nephrol 2012;16:238-43. https://doi.org/10.1007/s10157-011-0549-3
  6. Sato T, Liang K, Vaziri ND. Down-regulation of lipoprotein lipase and VLDL receptor in rats with focal glomerulosclerosis. Kidney Int 2002;61:157-62. https://doi.org/10.1046/j.1523-1755.2002.00104.x
  7. Liu S, Vaziri ND. Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome. Nephrol Dial Transplant 2014;29:538-43. https://doi.org/10.1093/ndt/gft439
  8. Morris AW. Nephrotic syndrome: PCSK9: a target for hypercholesterolaemia in nephrotic syndrome. Nat Rev Nephrol 2016;12:510. https://doi.org/10.1038/nrneph.2016.111
  9. Jin K, Park BS, Kim YW, Vaziri ND. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study. Am J Kidney Dis 2014;63:584-9. https://doi.org/10.1053/j.ajkd.2013.10.042
  10. Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982;2:1309-11.
  11. Clement LC, Mace C, Avila-Casado C, Joles JA, Kersten S, Chugh SS. Circulating angiopoietin-like 4 links proteinuria with hypertriglyceridemia in nephrotic syndrome. Nat Med 2014;20:37-46. https://doi.org/10.1038/nm.3396
  12. Vaziri ND, Liang K. Up-regulation of acyl-coenzyme A:cholesterol acyltransferase (ACAT) in nephrotic syndrome. Kidney Int 2002;61:1769-75. https://doi.org/10.1046/j.1523-1755.2002.00319.x
  13. Vaziri ND, Liang KH. Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome.Circulation 2004;110:419-25. https://doi.org/10.1161/01.CIR.0000136023.70841.0F
  14. Vaziri ND, Liang KH. Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis. Kidney Int 1995;48:1979-85. https://doi.org/10.1038/ki.1995.500
  15. Vaziri ND, Sato T, Liang K. Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis. Kidney Int 2003;63:1756-63. https://doi.org/10.1046/j.1523-1755.2003.00911.x
  16. Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 1993;44:638-42. https://doi.org/10.1038/ki.1993.292
  17. Mehta A, Mishra S, Ahmad K, Tiwari HC, Singh V, Singh A. Carotid intima media thickness in children with nephrotic syndrome: an observational case control study. Sudan J Paediatr 2019;19:110-6.
  18. Radhakrishnan J, Appel AS, Valeri A, Appel GB. The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. Am J Kidney Dis 1993;22:135-42. https://doi.org/10.1016/S0272-6386(12)70179-8
  19. Gyebi L, Soltani Z, Reisin E. Lipid nephrotoxicity: new concept for an old disease. Curr Hypertens Rep 2012;14:177-81. https://doi.org/10.1007/s11906-012-0250-2
  20. Chung JJ, Huber TB, Godel M, Jarad G, Hartleben B, Kwoh C, et al. Albumin-associated free fatty acids induce macropinocytosis in podocytes. J Clin Invest 2015;125:2307-16. https://doi.org/10.1172/JCI79641
  21. Allison SJ. Podocyte biology: free fatty acid-induced macropinocytosis in podocytes. Nat Rev Nephrol 2015;11:386. https://doi.org/10.1038/nrneph.2015.76
  22. Eddy AA, Michael AF. Acute tubulointerstitial nephritis associated with aminonucleoside nephrosis. Kidney Int 1988;33:14-23. https://doi.org/10.1038/ki.1988.3
  23. Eddy AA, McCulloch L, Liu E, Adams J. A relationship between proteinuria and acute tubulointerstitial disease in rats with experimental nephrotic syndrome. Am J Pathol 1991;138:1111-23.
  24. Cases A, Coll E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int Suppl 2005;(99):S87-93.
  25. D'Amico G, Gentile MG, Manna G, Fellin G, Ciceri R, Cofano F, et al. Effect of vegetarian soy diet on hyperlipidaemia in nephrotic syndrome. Lancet 1992;339:1131-4. https://doi.org/10.1016/0140-6736(92)90731-H
  26. Gentile MG, Fellin G, Cofano F, Delle Fave A, Manna G, Ciceri R, et al. Treatment of proteinuric patients with a vegetarian soy diet and fish oil. Clin Nephrol 1993;40:315-20.
  27. Hall AV, Parbtani A, Clark WF, Spanner E, Huff MW, Philbrick DJ, et al. Omega-3 fatty acid supplementation in primary nephrotic syndrome: effects on plasma lipids and coagulopathy. J Am Soc Nephrol 1992;3:1321-9. https://doi.org/10.1681/ASN.V361321
  28. Bell S, Cooney J, Packard CJ, Caslake MJ, Deighan CJ. The effect of omega-3 fatty acids on the atherogenic lipoprotein phenotype in patients with nephrotic range proteinuria. Clin Nephrol 2012;77:445-53. https://doi.org/10.5414/CN107450
  29. Rabelink AJ, Hene RJ, Erkelens DW, Joles JA, Koomans HA. Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome. Lancet 1988;2:1335-8.
  30. Thomas ME, Harris KP, Ramaswamy C, Hattersley JM, Wheeler DC, Varghese Z, et al. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney Int 1993;44:1124-9. https://doi.org/10.1038/ki.1993.358
  31. Wheeler DC, Bernard DB. Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. Am J Kidney Dis 1994;23:331-46. https://doi.org/10.1016/S0272-6386(12)80994-2
  32. Massy ZA, Ma JZ, Louis TA, Kasiske BL. Lipid-lowering therapy in patients with renal disease. Kidney Int 1995;48:188-98. https://doi.org/10.1038/ki.1995.284
  33. Kong X, Yuan H, Fan J, Li Z, Wu T, Jiang L, et al. Lipid-lowering agents for nephrotic syndrome. Cochrane Database Syst Rev 2013;(12):CD005425.
  34. Brown CD, Azrolan N, Thomas L, Roberts KG, Bostom A, Zhao ZH, et al. Reduction of lipoprotein(a) following treatment with lovastatin in patients with unremitting nephrotic syndrome. Am J Kidney Dis 1995;26:170-7. https://doi.org/10.1016/0272-6386(95)90171-X
  35. Khurana M, Silverstein DM. Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease. Pediatr Nephrol 2015;30:2073-84. https://doi.org/10.1007/s00467-015-3075-9
  36. Coleman JE, Watson AR. Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood. Pediatr Nephrol 1996;10:171-4. https://doi.org/10.1007/BF00862065
  37. Sanjad SA, al-Abbad A, al-Shorafa S. Management of hyperlipidemia in children with refractory nephrotic syndrome: the effect of statin therapy. J Pediatr 1997;130:470-4. https://doi.org/10.1016/S0022-3476(97)70213-0
  38. Groggel GC, Cheung AK, Ellis-Benigni K, Wilson DE. Treatment of nephrotic hyperlipoproteinemia with gemfibrozil. Kidney Int 1989;36:266-71. https://doi.org/10.1038/ki.1989.189
  39. Buyukcelik M, Anarat A, Bayazit AK, Noyan A, Ozel A, Anarat R, et al. The effects of gemfibrozil on hyperlipidemia in children with persistent nephrotic syndrome. Turk J Pediatr 2002;44:40-4.
  40. Jacobson TA. Myopathy with statin-fibrate combination therapy: clinical considerations. Nat Rev Endocrinol 2009;5:507-18. https://doi.org/10.1038/nrendo.2009.151
  41. Valeri A, Gelfand J, Blum C, Appel GB. Treatment of the hyperlipidemia of the nephrotic syndrome: a controlled trial. Am J Kidney Dis 1986;8:388-96. https://doi.org/10.1016/S0272-6386(86)80164-0
  42. Di Bartolo B, Scherer DJ, Brown A, Psaltis PJ, Nicholls SJ. PCSK9 inhibitors in hyperlipidemia: current status and clinical outlook. BioDrugs 2017;31:167-74. https://doi.org/10.1007/s40259-017-0220-y
  43. Haas ME, Levenson AE, Sun X, Liao WH, Rutkowski JM, de Ferranti SD, et al. The role of proprotein convertase subtilisin/kexin type 9 in nephrotic syndrome-associated hypercholesterolemia. Circulation 2016;134:61-72. https://doi.org/10.1161/CIRCULATIONAHA.115.020912
  44. Jatem E, Lima J, Montoro B, Torres-Bondia F, Segarra A. Efficacy and safety of PCSK9 inhibitors in hypercholesterolemia associated with refractory nephrotic syndrome. Kidney Int Rep 2020;6:101-9.
  45. Hattori M, Chikamoto H, Akioka Y, Nakakura H, Ogino D, Matsunaga A, et al. A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis 2003;42:1121-30. https://doi.org/10.1053/j.ajkd.2003.08.012
  46. Muso E. Beneficial effect of LDL-apheresis in refractory nephrotic syndrome. Clin Exp Nephrol 2014;18:286-90. https://doi.org/10.1007/s10157-013-0930-5
  47. Raina R, Krishnappa V. An update on LDL apheresis for nephrotic syndrome. Pediatr Nephrol 2019;34:1655-69. https://doi.org/10.1007/s00467-018-4061-9